摘要
目的 :观察尿激酶 (UK)和链激酶 (SK)在急性心肌梗塞 (AMI)治疗中的溶栓效果和不良反应 ,对其安全性和疗效作出评估。方法 :2 0 0 0年 1月~ 2 0 0 1年 5月对 5 0例AMI患者分别给予 15 0万IUUK或者 15 0万IUSK治疗 ,观察溶栓再通率、急性期死亡率、不良反应发生率。结果 :溶栓再通率 15 0万IUUK70 .5 9% ,15 0万IUSK6 8.75 % ;急性期死亡率 15 0万IUUK11.76 % ,15 0万IUSK12 .5 0 % ;不良反应发生率 ,15 0万IUUK与上消化道出血 2 .94 %、脑出血 2 .94 % ;15 0万IUSK上消化道出血 6 .2 5 %、脑出血 6 .2 5 %。结论 :15 0万IUUK与 15 0万IUSK的再通率、不良反应发生率。
Objective:To investigate the efficacy and side effect of Urokinase(UK)and Streptikinase(SK)in thrombolytic treatment of AMI. Methods: 50 patients with AMI were administrated with UK or SK randomizedly. The rates of repercussion, mortality and incidence of side effect were observed and compared. Results:The repercussion rate of UK and SK were 70.59% and 68.75%, respectively. The mortality in UK group was 11.76% compared with 12.5% in SK group. The incidence of upper digestive tract hemorrhage and cerebral hemorrhage were 2.94% and 2.94%, respectively, in UK group compared with 6.25% and 6.25% in SK group. Conclusion: There is no statistic significant difference of repercussion rate, mortality, and incidence of side effect between UK and SK groups.
出处
《实用临床医学(江西)》
CAS
2002年第A01期61-62,共2页
Practical Clinical Medicine
关键词
急性心肌梗塞
尿激酶
链激酶
血栓溶解疗法
acute myocardial infarction
urokinase
streptokinase
thrombolysis